Finanzen von Mesoblast Ltd (MESO)MESOMesoblast Ltd

In the context of the broader market, MESO competes directly with industry leaders such as CLDX and MBX. With a market capitalization of $1.86B, it holds a significant position in the sector. When comparing efficiency, MESO's gross margin of N/A stands against CLDX's 100.00% and MBX's N/A. Such benchmarking helps identify whether Mesoblast Limited is trading at a premium or discount relative to its financial performance.

Mesoblast reported a revenue of $120.3 million for FY 2026, a 600% increase from $17.2 million in the previous year, with a narrowed net loss of $57.5 million, down 44% from $102.1 million.